Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20109923 | 0.90 | DPP8 (0.33) | DPP4 | |
| SCHEMBL19229743 | 0.81 | MEN1 (0.45) | MEN1POLBMAPTKMT2ALIPE | |
| SCHEMBL20937305 | 0.80 | KCNH2 (0.33) | MEN1POLBKMT2AALDH1A1 | |
| SCHEMBL20247966 | 0.78 | ALDH1A1 (0.51) | MEN1POLBMAPTKMT2AALDH1A1 | |
| SCHEMBL20109395 | 0.77 | PTPN1 (0.31) | — | |
| SCHEMBL13509602 | 0.77 | PIK3CD (0.41) | MEN1POLBMAPTKMT2ALIPE | |
| SCHEMBL19229738 | 0.76 | MEN1 (0.41) | MEN1POLBMAPTKMT2AALDH1A1 | |
| SCHEMBL27373527 | 0.76 | DPP4 (0.37) | MEN1POLBMAPTKMT2AALDH1A1 | |
| SCHEMBL18327482 | 0.75 | CHRNB2 (0.40) | MEN1POLBMAPTKMT2ALIPE | |
| SCHEMBL29889243 | 0.75 | ALDH1A1 (0.39) | MEN1POLBMAPTKMT2ALIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844077-B2 | Thiazolyl-containing compounds for treating proliferative diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| EP-3715346-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | Dana-Farber Cancer Institute (US) | 2020-09-30 | — | — | EP | disclosed |
| US-20200165267-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-20170233411-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165267-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | BTK, BCL9L, MCL1 | MEN1 3398/4885POLB 1734/4885MAPT 4224/4885 |
| US-20170233411-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | BTK, BCL9L, BCL9 | MEN1 3621/4885POLB 1744/4885MAPT 4161/4885 |
| US-10844077-B2 | Thiazolyl-containing compounds for treating proliferative diseases | BTK, BCL9L, MCL1 | MEN1 3398/4885POLB 1734/4885MAPT 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.